Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study

NACompletedINTERVENTIONAL
Enrollment

14,263

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

October 27, 2022

Study Completion Date

January 31, 2024

Conditions
Colorectal CancerAdvanced AdenocarcinomaSerrated Polyp
Interventions
DIAGNOSTIC_TEST

ColoSense

"ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.~A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals."

Trial Locations (2)

63146

Geneoscopy, Inc., St Louis

78738

Elligo Health Research, Austin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Geneoscopy, Inc.

INDUSTRY

NCT04739722 - Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study | Biotech Hunter | Biotech Hunter